Lonza Invests $414 Million to Expand Biomanufacturing ServicesBy
Lonza has invested CHF 400 million ($414 million) to add two new biomanufacturing services (Ibex Design and Ibex Develop) as part of its Ibex Solutions package from the company’s 100,000-square meter biopark in Visp, Switzerland.
Lonza’s first Ibex offering, Ibex Dedicate, a modular, technology-agnostic biomanufacturing concept, was launched in July 2017. Ibex Dedicate offers a facility concept with reduced capital expenditure and accelerated timelines to enable speed to market or allow biopharmaceutical companies to delay investment decisions to decrease financial risk.
The two new Ibex Solutions, Ibex Design and Ibex Develop, are designed to service biotechnology companies with antibody therapies. Ibex Design and Ibex Develop will become operational from 2020 and provide manufacturing options from early development through to full commercialization. These services apply single-use and automation technologies.
Ibex Design covers the early stages of creating a new biologic, from gene through to clinical Phase I. The offering comprises a fixed-price gene-to-vial package with terms under which Lonza will deliver drug product based on at least 1 kg of drug substance within 12 months.The package also includes the reservation of a manufacturing slot for clinical resupply.
Ibex Develop helps companies transition from clinical Phase II to commercialization. The service is designed to enable biologics license applications to be submitted within 22 months from the start of process characterization.